Cue Biopharma, Inc. (NASDAQ: CUE) is a Healthcare company (Biotechnology) with a market capitalization of $92M. The Maz Rating grades it against the other companies in its sector.
Cue Biopharma, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $12.60, Cue Biopharma, Inc. trades at 2.9x sales. Over the last twelve months it generated about $32M of revenue and a net loss of $192M. It runs a gross margin of 99.5%, an operating margin of -387.8% and a net margin of -579.9%. It shows return on equity of -1641.9%, return on invested capital of -238.5% and a free cash flow yield of -49.0%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 0.00. Over the past 52 weeks the share price ranged from $4.97 to $45.50, with a beta of 2.81.
Cue Biopharma, Inc. does not currently pay a dividend.
9 Wall Street analyst ratings cover the stock: 9 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical enterprise focused on creating biological therapies. Its central objective is the precise manipulation of the human immune system to address a spectrum of severe conditions, such as various cancers, chronic infectious diseases, and autoimmune disorders. The company's leading investigational therapeutic is CUE-101, a specialized fusion protein biologic. This candidate is currently advancing through Phase 1b clinical trials, engineered to specifically identify and activate antigen-specific T cells involved in cancers originating from human papillomavirus. Beyond its flagship program, Cue Biopharma is also developing a range of other innovative platforms: CUE-102, another fusion protein biologic designed to stimulate specific T cells to combat cancer; CUE-103, an Immuno-STAT from the CUE-100 series, which is developed to target the KRAS G12V mutation relevant in diseases like colorectal, lung, and pancreatic cancers; CUE-200, which concentrates on cell surface receptors such as CD80 and/or 4-1BBL to counteract T cell exhaustion often seen in chronic infections; and the CUE-300 and CUE-400 frameworks, conceptual platforms aimed at treating diverse autoimmune conditions. Cue Biopharma maintains key strategic alliances, including collaborations with Merck Sharp & Dohme Corp. for the research and development of its unique biologics targeting autoimmune indications, with LG Chem Life Sciences for advancing Immuno-STATs in the field of oncology, and with the Albert Einstein College of Medicine. The company, founded in 2014, was initially known as Imagen Biopharma, Inc. before adopting its current name, Cue Biopharma, Inc., in October 2016. It is headquartered in Cambridge, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Cue Biopharma, Inc. (CUE) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 37.5% / 30% · Interest income / Revenue 365.9% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 37.5% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 365.9% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 37.5% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 365.9% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 3.35% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 69.5% / 33.33% · Receivables / Avg Assets (4Q) 12.8% / 33.33% · Interest income / Revenue 365.9% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 86.1% / 33.33% · (Cash+Recv) / Total Assets 86.1% / 33.33% · Interest income / Revenue 365.9% / 5% | Fail |
No. As of September 2026, Cue Biopharma, Inc. (CUE) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Cue Biopharma, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 365.9% of each dividend: Cue Biopharma, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.